Building a Payer-Specific Root Cause Registry to Drive Infusion Denial Recovery

Payer-specific root-cause denial management for infusion claims starts with a structured registry that links each denial to what caused it, by payer, drug, and denial code. Its purpose is to turn remittance and appeal data into two actions, recovering claims that can still be paid and fixing the upstream failures that keep producing denials. A denial queue tracks unfinished work. The registry explains why that work keeps coming back.

Why infusion denial management produces firefighting instead of recovery

The same denials return from the same payers, and billing teams send the same appeals. Each claim gets attention, but the pattern does not. When teams handle each denial on its own, a gap in documentation can look like a change in payer policy. The first may need a corrected submission. The second will keep causing denials until someone finds out what changed.

That distinction is harder to make as payers use AI adjudication systems with proprietary clinical edits, documentation thresholds, and bundling rules. Providers cannot see every update coming. Sift Healthcare’s Fourth Annual Denials Insights Report identifies denial activity moving upstream and fragmenting across workflows, including post-payment recoupments. A single denial queue no longer shows all the revenue at risk.

Infusion makes that blind spot expensive. When a buy-and-bill claim is denied, the practice is left with $5,000 to $50,000 per infusion encounter in drug acquisition cost. It needs different handling from a low-dollar E/M denial, but the time to recover payment may run out before a generalist team sees the pattern. A registry gives that pattern a place to surface across claims.

What a payer-specific root cause registry actually is, and what it is not

A payer-specific root cause registry maps denials to their actual causes at the intersection of payer, drug or J-code, CARC/RARC code, and service line. The returned code is only the starting point. An entry might retain CARC 197 while identifying the cause as “step therapy not documented.” That distinction connects the payer’s response to a failure the practice can address.

A denial rate report measures frequency. A clearinghouse scrub log captures pre-adjudication rejections, while the registry captures denials after adjudication. An appeals queue tracks the work awaiting action. A useful starting entry includes payer and plan type, drug and J-code, returned CARC and RARC codes, root cause, denial and appeal dates, appeal outcome, and whether a prevention action followed. Those fields connect the original denial to both its recovery history and its operational fix.

How payer adjudication behavior differs in ways that make a shared registry insufficient

UnitedHealthcare’s Commercial Reimbursement Policy states that it uses a customized Optum Claims Editing System to process claims under its reimbursement policies. Its bundling behavior therefore needs payer-specific analysis to determine where CMS rules explain the results. BCBS has different medical necessity criteria for each state plan. Even with a common classification system, the registry needs separate records for each payer and plan.

UHC’s provider appeals page says deadlines for peer-to-peer requests depend on the case type and the state guidelines that apply. It allows 3 business days from posted denial for inpatient cases and 21 calendar days for outpatient cases, but says most reviews need to be requested within 24 hours. BCBS appeal windows vary by state plan. Each payer needs its own stored deadline, and the peer-to-peer deadline must be kept separate from the broader appeal process.

The CMS Interoperability and Prior Authorization Final Rule requires time frames for decisions and requires denial rates to be reported to the public. It does not standardize clinical criteria. A registry must therefore preserve the payer’s specific reason for denial even where response-time requirements are more consistent.

Building the registry from remittance and appeal data

To build the registry, start with the electronic remittance advice, or ERA, at both claim and line level. On the same claim, a drug line and an administration line can be denied for different reasons. Keep those reasons separate. Then connect the remittance to the payer portal’s denial letter, which may identify a clinical rationale, policy number, or criteria version that the ERA omits.

Next, add the results of appeals and the correspondence about prior authorization. A successful appeal shows which evidence or argument met that payer’s threshold, while a failed appeal records an approach that did not. Authorization denials and reauthorization approvals add the documentation requirements applied to a particular drug and indication. These records already exist in the workflow. The missing step is usually consistent classification.

A practical starting taxonomy groups causes under prior authorization, medical necessity, coding and units, eligibility and coordination of benefits, and payer policy. Within those groups, record the specific failure, such as an expired authorization, missing comorbidity, J-code unit error, coverage lapse, or site-of-care restriction. This is a working scheme. Its usefulness depends on applying the same distinctions each time rather than copying the returned code into a field called root cause.

How do you stop recurring infusion denials while recovering claims that can still be paid?

The registry separates one-time errors from recurring failures by looking across claims. A single CARC 197 denial on a Remicade claim at UHC is a case to investigate. The same code appearing on every third reauthorization cycle across multiple Remicade patients points to a reauthorization workflow gap. That pattern needs more than another appeal letter. It needs a change before the next authorization expires.

To recover payment, the team should use the payer-drug record to find high-dollar biologic denials, check which deadline applies, and choose an appeal based on what has worked before. A denied infliximab or tocilizumab claim puts acquisition cost at risk. Stored outcomes can show whether an NCCI table citation has succeeded for a UHC modifier bundling dispute. That gives the team a more specific starting point than a generic appeal.

For prevention, the same record should direct the fix to where the failure begins. Recurring reauthorization lapses call for a scheduling trigger at the payer’s required interval. Repeated BCBS denials for undocumented step therapy call for a prompt in the clinical notes at the point of care. Repeated site-of-care or white-bagging denials call for a coverage and contracting response. Recovery and prevention are not competing uses of the registry, and a recurring denial may require both.

Prior authorization as the highest-volume source of registry signal for infusion practices

Most infusion biologics require reauthorization at defined dosing intervals. Payers also set step therapy requirements, biosimilar preferences, and dose or frequency limits, which differ by payer and can change without the provider being told. The last approval is not a permanent specification. The registry records the thresholds appearing in current authorization decisions so the practice is not relying only on what worked before.

That requires more than logging “PA denied.” Each entry should capture the cited policy number, step therapy requirement, or biosimilar preference and connect it to the payer, plan, drug, and indication. Those details go into the practice’s library of payer requirements for high-volume drugs. They also show where a repeated denial reflects a tracking lapse.

When entries reveal a UHC authorization pattern for a biologic, the response should use UHC’s requirements. Reauthorization starts at the interval it requires, documentation is checked against its clinical criteria, and peer-to-peer escalation takes place within the window that applies to the case. The registry supplies the evidence for that protocol. It keeps another payer’s timetable from becoming the practice’s default.

J-code and unit-level registry entries as the detection mechanism for buy-and-bill underpayment patterns

Underpayments can escape a denial queue because they post as paid and generate no denial code. Detecting them systematically requires line-level comparison against contracted reimbursement. The registry then gives those variances a place to accumulate by payer and drug. Payment is not proof of correct reimbursement.

An underpayment entry therefore differs from a denial entry. Instead of relying on a CARC code, it records expected reimbursement from the contract, actual payment, the variance, and the identified cause. That cause may be a fee schedule mismatch, incorrect unit application, or contract pricing not applied by the payer’s system. For the drug line, J-code units are calculated by dividing the administered dose by the J-code unit size. Dose adjustments, vial splits, and weight-based dosing changes can introduce errors that recur on the same code.

New biologics billed under not-otherwise-classified codes or temporary Q-codes need to be watched more closely because payers may price them in different ways before permanent J-code reimbursement is in place. Code status belongs in the record for that reason. For practices eligible under federal drug-pricing programs, modifier tracking adds another layer. Recording JG modifier usage by drug and payer helps identify systematic errors before they accumulate into audit exposure or recoupment demands.

How registry signal shapes AR prioritization for high-dollar infusion claims

Aging buckets show how long a claim has waited but leave out how much time is left to recover payment. For an infusion claim denied at day 1, the time to request peer-to-peer may run out well before a standard 90-day aging review. The registry connects the denial cause to the payer’s deadline and the practice’s history of recovering that type of claim.

To put that signal into AR work, teams should segment open claims by payer and drug as well as age. The team needs to judge the urgency of a 45-day-old denied infliximab claim at UHC differently from that of a 45-day-old denied administration claim at BCBS. Stored outcomes help teams estimate the chance of recovery by payer and root cause, while the deadline and dollars at risk help set the order of work. Claims tied to recurring post-payment recoupments need a separate response even after payment posts.

These choices are visible in operating results. Days in AR and first-pass denial rates are measures used in infusion operational benchmarking and M&A diligence, where Days in AR below 45 days is treated as healthy. The registry shows the details of the work behind those measures. An aging report alone cannot show which upstream change would improve them.

Maintaining the registry as a living operational document rather than a historical archive

A registry that is out of date can steer teams toward appeals that no longer work. Its completeness at launch is not enough. UHC’s Commercial Reimbursement Policy states that rebundling edits are updated quarterly, while BCBS medical necessity criteria change on schedules that vary by state plan. Medicare Advantage plans can also revise authorization lists mid-year. Each root cause entry needs a validation date in addition to the date of the original denial.

The maintenance process should respond to changes in the work itself. A new denial type at a payer should trigger review for a possible policy or algorithm change. A previously successful appeal strategy that begins failing should prompt reassessment of the criteria and template. A new formulary drug, or a J-code assigned to a drug previously billed under a not-otherwise-classified code, needs its own payer-drug entries from the first claim forward.

A named owner makes those updates accountable. That person’s performance measures should cover how accurate and up to date the registry is, as well as appeal results. Without that responsibility, updates become another backlog.

Where Ruby fits in the registry-driven denial recovery model

Ruby is built for infusion and buy-and-bill specialty billing, covering benefits verification and prior authorization through claims submission, denial management, payment posting, and AR. Those workflows are where the registry’s evidence originates and where its findings must change the work. Payer-drug detail connects the steps. Without it, authorization history, denial rationale, and payment variance are kept in separate records that fail to explain why revenue was lost.

The classification step still requires judgment. Two denials with the same CARC code can need different documentation, appeals, or upstream corrections. Ruby pairs automation with experienced operators who understand how infusion payers handle claims and can tell the returned code apart from the actual cause. Its place in this model is to connect infusion-specific analysis to the authorization, recovery, and payment workflows where the practice can act on it.